These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 6579509

  • 1. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T, Krykowski E, Płuzańska A, Olszańska-Skorek T, Urbańska-Ryś H, Polkowska-Kulesza E, Błasińska-Morawiec M, Mazurowa A.
    Pol Tyg Lek; 1983 Apr 18; 38(16):481-4. PubMed ID: 6579509
    [No Abstract] [Full Text] [Related]

  • 2. [Four cases of therapy-related leukemia in multiple myeloma].
    Natori K, Izumi H, Kaneko K, Ishihara S, Nagase D, Fujimoto Y, Kato M, Umeda M, Kuraishi Y.
    Gan To Kagaku Ryoho; 2007 Jan 18; 34(1):121-4. PubMed ID: 17220686
    [Abstract] [Full Text] [Related]

  • 3. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 4. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y, Karitani Y, Tanaka I, Kobayashi T, Ohno T, Kageyama S, Katayama N, Kataoka Y, Kamio N, Ohota C.
    Rinsho Ketsueki; 1984 Sep 15; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract] [Full Text] [Related]

  • 5. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA, Houwen B, Piersma H, Marrink J, Ockhuizen T, Halie MR, Nieweg HO.
    Neth J Med; 1984 Sep 15; 27(2):25-30. PubMed ID: 6709108
    [No Abstract] [Full Text] [Related]

  • 6. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
    Bladé J, Urbano A, López Guillermo A, Rozman M, Rovira M, Montserrat E, Rozman C.
    Sangre (Barc); 1990 Apr 15; 35(2):93-7. PubMed ID: 2363100
    [Abstract] [Full Text] [Related]

  • 7. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B, Smith L, Alexanian R.
    N Engl J Med; 1984 May 24; 310(21):1353-6. PubMed ID: 6546971
    [Abstract] [Full Text] [Related]

  • 8. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
    Wutke K, Anger G.
    Z Gesamte Inn Med; 1983 Dec 01; 38(23):630-3. PubMed ID: 6689459
    [Abstract] [Full Text] [Related]

  • 9. Myelopathies during the course of multiple myeloma.
    Economopoulos T, Pappa V, Panani A, Stathakis N, Dervenoulas J, Papageorgiou E, Asprou N, Raptis S.
    Haematologica; 1991 Dec 01; 76(4):289-92. PubMed ID: 1794735
    [Abstract] [Full Text] [Related]

  • 10. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U, Crivellari D, Carbone A, Veronesi A, Galligioni E, Trovò MG, Tumolo S, Grigoletto E.
    Cancer Treat Rep; 1982 Nov 01; 66(11):1971-3. PubMed ID: 6897205
    [Abstract] [Full Text] [Related]

  • 12. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
    Scheithauer W, Cortelezzi A, Fritz E, Kührer I, Polli E, Baldini L, Ludwig H.
    J Biol Response Mod; 1989 Apr 01; 8(2):109-15. PubMed ID: 2659740
    [Abstract] [Full Text] [Related]

  • 13. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Apr 01; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 14. Results and further perspectives of plasmocytoma chemotherapy.
    Sakalová A, Hrubisko M, Gazová S, Steruská M, Prümmerová J.
    Neoplasma; 1986 Apr 01; 33(2):251-8. PubMed ID: 3520353
    [Abstract] [Full Text] [Related]

  • 15. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A.
    J Clin Oncol; 1993 Jun 01; 11(6):1165-71. PubMed ID: 8501503
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C, Sevilla F, Zapatero A, Blanco L, Sabán J, Serrano M, Serrano Ríos M.
    Rev Clin Esp; 1985 May 01; 176(8):392-5. PubMed ID: 3839590
    [No Abstract] [Full Text] [Related]

  • 17. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S, Writing Committee of the "Bologna 90" Clinical Trial.
    Haematologica; 2002 Sep 01; 87(9):934-42. PubMed ID: 12217805
    [Abstract] [Full Text] [Related]

  • 18. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
    Leoni P, Salvi A, Brianzoni MF, Centurioni R, Montillo M, Olivieri A.
    G Clin Med; 1986 Dec 01; 67(5-6):291-6. PubMed ID: 3609590
    [No Abstract] [Full Text] [Related]

  • 19. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S.
    Cancer; 2003 Jan 01; 97(1):21-9. PubMed ID: 12491501
    [Abstract] [Full Text] [Related]

  • 20. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.
    Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.